Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin.

Kim JE, Cho HJ, Kim JS, Shim CK, Chung SJ, Oak MH, Yoon IS, Kim DD.

Xenobiotica. 2013 Jul;43(7):579-91. doi: 10.3109/00498254.2012.751140. Epub 2012 Dec 19.

PMID:
23252722
2.

Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.

Choi JS, Piao YJ, Kang KW.

Arch Pharm Res. 2011 Apr;34(4):607-13. doi: 10.1007/s12272-011-0411-x. Epub 2011 May 5.

PMID:
21544726
3.

Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.

Choi SJ, Shin SC, Choi JS.

Arch Pharm Res. 2011 Feb;34(2):309-15. doi: 10.1007/s12272-011-0217-x. Epub 2011 Mar 6.

PMID:
21380815
5.

Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.

Dufek MB, Bridges AS, Thakker DR.

Drug Metab Dispos. 2013 Sep;41(9):1695-702. doi: 10.1124/dmd.113.052191. Epub 2013 Jul 2.

6.

Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.

Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Liu PQ, Duan W, Chowbay B, Wen JY, Li CG, Zhou SF.

Curr Drug Metab. 2007 May;8(4):325-40.

PMID:
17504222
7.

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

Kamath AV, Wang J, Lee FY, Marathe PH.

Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11.

PMID:
17429625
8.
9.

P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.

Yang C, Zhang T, Li Z, Xu L, Liu F, Ruan J, Liu K, Zhang Z.

Toxicol Appl Pharmacol. 2013 Dec 15;273(3):561-8. doi: 10.1016/j.taap.2013.09.030. Epub 2013 Oct 9.

PMID:
24120885
10.

In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.

Abuasal BS, Bolger MB, Walker DK, Kaddoumi A.

Mol Pharm. 2012 Mar 5;9(3):492-504. doi: 10.1021/mp200275j. Epub 2012 Feb 2.

PMID:
22264132
11.

Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506).

Qin XL, Bi HC, Wang XD, Li JL, Wang Y, Xue XP, Chen X, Wang CX, Xu le J, Wang YT, Huang M.

Int J Pharm. 2010 Apr 15;389(1-2):114-21. doi: 10.1016/j.ijpharm.2010.01.025. Epub 2010 Jan 25.

PMID:
20097278
12.
13.

Emulsion-based colloidal nanosystems for oral delivery of doxorubicin: improved intestinal paracellular absorption and alleviated cardiotoxicity.

Kim JE, Yoon IS, Cho HJ, Kim DH, Choi YH, Kim DD.

Int J Pharm. 2014 Apr 10;464(1-2):117-26. doi: 10.1016/j.ijpharm.2014.01.016. Epub 2014 Jan 21.

PMID:
24463005
14.

P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.

Kamath AV, Chong S, Chang M, Marathe PH.

Cancer Chemother Pharmacol. 2005 Feb;55(2):110-6. Epub 2004 Aug 27.

PMID:
15338193
15.

Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.

Ikemura K, Urano K, Matsuda H, Mizutani H, Iwamoto T, Okuda M.

J Pharmacol Exp Ther. 2009 Jan;328(1):249-55. doi: 10.1124/jpet.108.145581. Epub 2008 Oct 8.

16.

Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system.

Ke W, Zhao Y, Huang R, Jiang C, Pei Y.

J Pharm Sci. 2008 Jun;97(6):2208-16.

PMID:
17879294
17.
18.

P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.

Dufek MB, Knight BM, Bridges AS, Thakker DR.

Drug Metab Dispos. 2013 Mar;41(3):642-50. doi: 10.1124/dmd.112.049965. Epub 2013 Jan 3.

20.

Transport mechanism of doxorubicin loaded chitosan based nanogels across intestinal epithelium.

Feng C, Sun G, Wang Z, Cheng X, Park H, Cha D, Kong M, Chen X.

Eur J Pharm Biopharm. 2014 May;87(1):197-207. doi: 10.1016/j.ejpb.2013.11.007. Epub 2013 Dec 4.

PMID:
24316340

Supplemental Content

Support Center